MPM BioVentures Strategic Fund LP

CIK 1360529 · last filed 2007-11-13

MPM BioVentures Strategic Fund LP is a corporate insider who has filed 1 SEC Form 4 insider transactions across 1 company since 2007. The most recent filing, for ARYX, was dated Nov 13, 2007. Across all open-market trades the lifetime net is +$24.0M, making them a net buyer over the disclosed history. The firm reports its address in Boston, MA. 16 SEC filings were submitted jointly with MPM BIOVENTURES III PARALLEL FUND, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

1

Total Filings

1

Lifetime Open-Market Net

$24.00M

Filer Profile

Reported Address

THE JOHN HANCOCK TOWER
200 CLARENDON STREET 54TH FLOOR
BOSTON, MA 02116

Phone

(617) 425-9200

State of Incorporation

Related Filers

MPM BIOVENTURES III PARALLEL FUND, L.P. — 16 joint filings, latest 2013-02-07

Ashley L. Dombkowski — 10 joint filings, latest 2009-11-13

LUKE EVNIN — 10 joint filings, latest 2009-11-13

ANSBERT GADICKE — 10 joint filings, latest 2009-11-13

William Greene — 10 joint filings, latest 2009-11-13

VAUGHN M KAILIAN — 10 joint filings, latest 2009-11-13

MPM Asset Management Investors 2004 BVIII LLC — 10 joint filings, latest 2009-11-13

Steven St Peter — 10 joint filings, latest 2009-11-13

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
ARYx Therapeutics, Inc. (ARYX) Delisted	10%+ Owner	3,276,862	—	—	$24.00M	1	2007-11-13

Recent Filings

1 filing

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2007-11-13	ARYx Therapeutics, Inc. (ARYX) Delisted	Mixed	+28,614,896	$24.00M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.